Antiviral Research

Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro.  194. 2021

Clinical outcome and the role of antivirals in congenital cytomegalovirus infection.  191. 2021

Isocotoin suppresses hepatitis E virus replication through inhibition of heat shock protein 90.  185. 2021

Mark Prichard: Scholar, family man and friend.  176. 2020

NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions.  170. 2019

New therapies for human cytomegalovirus infections.  159:153-174. 2018

Comparison of antiviral resistance across acute and chronic viral infections.  158:103-112. 2018

Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures.  150:164-173. 2018

Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection.  83:207-213. 2009

The Effect of Human Cytomegalovirus Proteins PUL97 and PUL27 on Host Interferon Responses.  82:A47-A47. 2009

Herpes simplex encephalitis: Adolescents and adults.  71:141-148. 2006

Recent development of therapeutics for chronic HCV infection.  71:351-362. 2006

Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis.  63:141-151. 2004

HSV shedding.  63. 2004

HSV-2 transmission.  63. 2004

Lessons from HIV and hepatitis viruses.  63. 2004

Introduction: Is viral shedding a surrogate marker for transmission of genital herpes?.  63. 2004

Smallpox: A potential agent of bioterrorism.  57:7-12. 2003

Juvenile onset recurrent respiratory papillomatosis: Possibilities for successful antiviral therapy.  45:83-93. 2000

Herpes zoster: Focus on treatment in older adults.  44:145-154. 1999

Effect of recombinant human interferon α B/D (rHu-IFN-α B/D) in combination with acyclovir in experimental HSV-1 encephalitis.  44:75-78. 1999

Comparison of antiviral compounds against human herpesvirus 6 and 7.  40:73-84. 1998

Summary of the III international consensus symposium on combined antiviral therapy.  38:75-93. 1998

A randomized, double-blind trial of parenteral low dose versus high dose interferon-β in combination with cryotherapy for treatment of condyloma acuminatum.  35:41-52. 1997

Assessment of pain in herpes zoster: Lessons learned from antiviral trials.  33:73-85. 1997

Summary of the International Consensus Symposium on advances in the diagnosis, treatment and prophylaxis of cytomegalovirus infection.  32:119-140. 1996

Differential effect of recombinant human and mouse interferons on replication of herpes simplex virus type 1 in mouse cells.  32:27-34. 1996

Unique clinical trial design: Combination acyclovir plus prednisone therapy of localized zoster in the normal host.  29:67-68. 1996

Antiviral resistance - an emerging problem.  26:365-368. 1995

Antiviral resistance in clinical practice.  26:423-438. 1995

Assays for antiviral drug resistance.  26:403-413. 1995

Models of antiviral resistance.  26:415-422. 1995

Molecular mechanisms of antiviral resistance.  26:369-401. 1995

Research initiatives in studies of antiviral resistance and consensus points and recommendations.  26:439-452. 1995

Antiviral effect of the extract of culture medium of Lentinus edodes mycelia on the replication of herpes simplex virus type 1.  20:293-303. 1993

SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.  21:15-35. 1993

Interference with HIV-1 reverse transcriptase-catalyzed DNA chain elongation by the 5′-triphosphate of the carbocyclic analog of 2′-deoxyguanosine.  19:325-332. 1992

Effect of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine on the replication and morphogenesis of herpes simplex virus type 1.  19:181-192. 1992

Editorial.  11:1-2. 1989